U.S. General Anesthesia Drugs Market (2025 - 2030) Size, Share & Trends Analysis Report By Drug (Propofol, Sevoflurane), By Route Of Administration (Intravenous, Inhaled), By End-use (Hospitals, Ambulatory Surgical Centers), By Application, By Country, And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation & Scope
                    1.2. Segment Definitions
                        1.2.1. Drug
                        1.2.2. Route of Administration
                        1.2.3. End Use
                        1.2.4. Application
                        1.2.5. Regional scope
                        1.2.6. Estimates and forecasts timeline
                    1.3. Research Methodology
                    1.4. Information Procurement
                        1.4.1. Purchased database
                        1.4.2. GVR’s internal database
                        1.4.3. Secondary sources
                        1.4.4. Primary research
                        1.4.5. Details of primary research
                            1.4.5.1. Data for primary interviews in North America
                    1.5. Information or Data Analysis
                        1.5.1. Data analysis models
                    1.6. Market Formulation & Validation
                    1.7. Model Details
                        1.7.1. Commodity flow analysis (Model 1)
                        1.7.2. Approach 1: Commodity flow approach
                    1.8. List of Secondary Sources
                    1.9. List of Primary Sources
                    1.10. Objectives
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Outlook
                        2.2.1. Drug Outlook
                        2.2.2. Route of Administration
                        2.2.3. End Use
                        2.2.4. Application
                        2.2.5. Regional outlook
                    2.3. Competitive Insights
Chapter 3. U.S. General Anesthesia Drugs Market Variables, Trends & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent market outlook
                        3.1.2. Related/ancillary market outlook
                    3.2. Market Dynamics
                        3.2.1. Market driver analysis
                            3.2.1.1. Increasing Volume Of Surgical Procedures
                            3.2.1.2. Advancements In Anesthesia Technology
                            3.2.1.3. Regulatory Developments
                        3.2.2. Market restraint analysis
                            3.2.2.1. Regulatory and Compliance Challenges
                            3.2.2.2. Adverse Effects and Safety Concerns
                    3.3. U.S. General Anesthesia Drugs Market Analysis Tools
                        3.3.1. Industry Analysis - Porter’s
                            3.3.1.1. Supplier power
                            3.3.1.2. Buyer power
                            3.3.1.3. Substitution threat
                            3.3.1.4. Threat of new entrant
                            3.3.1.5. Competitive rivalry
                        3.3.2. PESTEL Analysis
                            3.3.2.1. Political landscape
                            3.3.2.2. Technological landscape
                            3.3.2.3. Economic landscape
Chapter 4. U.S. General Anesthesia Drugs Market: Drug Estimates & Trend Analysis
                    4.1. U.S. General Anesthesia Drugs Market: Drug Dashboard
                    4.2. U.S. General Anesthesia Drugs Market: Drug Movement Analysis
                    4.3. U.S. General Anesthesia Drugs Market by Drug, Revenue
                    4.4. Sevoflurane
                        4.4.1. Sevoflurane market estimates and forecasts 2018 to 2030 (USD Million)
                    4.5. Propofol
                        4.5.1. Propofol market estimates and forecasts 2018 to 2030 (USD Million)
                    4.6. Dexmedetomidine
                        4.6.1. Dexmedetomidine market estimates and forecasts 2018 to 2030 (USD Million)
                    4.7. Remifentanil
                        4.7.1. Remifentanil market estimates and forecasts 2018 to 2030 (USD Million)
                    4.8. Desflurane
                        4.8.1. Desflurane market estimates and forecasts 2018 to 2030 (USD Million)
                    4.9. Midazolam
                        4.9.1. Midazolam market estimates and forecasts 2018 to 2030 (USD Million)
                    4.10. Others
                        4.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. U.S. General Anesthesia Drugs Market: Route of Administration Estimates & Trend Analysis
                    5.1. U.S. General Anesthesia Drugs Market: Route of Administration Dashboard
                    5.2. U.S. General Anesthesia Drugs Market: Route of Administration Movement Analysis
                    5.3. U.S. General Anesthesia Drugs Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
                    5.4. Intravenous
                        5.4.1. Intravenous market estimates and forecasts 2018 to 2030 (USD Million)
                    5.5. Inhaled
                        5.5.1. Inhaled market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. U.S. General Anesthesia Drugs Market: End Use Estimates & Trend Analysis
                    6.1. U.S. General Anesthesia Drugs Market: End Use Dashboard
                    6.2. U.S. General Anesthesia Drugs Market: End Use Movement Analysis
                    6.3. U.S. General Anesthesia Drugs Market Estimates and Forecasts, By End Use, Revenue (USD Million)
                    6.4. Hospitals
                        6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
                    6.5. Ambulatory Surgical Centers
                        6.5.1. Ambulatory Surgical Centers market estimates and forecasts 2018 to 2030 (USD Million)
                    6.6. Others
                        6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. U.S. General Anesthesia Drugs Market: Application Estimates & Trend Analysis
                    7.1. U.S. General Anesthesia Drugs Market: Application Dashboard
                    7.2. U.S. General Anesthesia Drugs Market: Application Movement Analysis
                    7.3. U.S. General Anesthesia Drugs Market Estimates and Forecasts, By Application, Revenue (USD Million)
                    7.4. Heart Surgeries
                        7.4.1. Heart Surgeries market estimates and forecasts 2018 to 2030 (USD Million)
                    7.5. Cancer
                        7.5.1. Cancer market estimates and forecasts 2018 to 2030 (USD Million)
                    7.6. General Surgery
                        7.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
                    7.7. Knee and hip replacements
                        7.7.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
                    7.8. Other
                        7.8.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. U.S. General Anesthesia Drugs Market: Regional Estimates & Trend Analysis by Drug, Route of Administration, End Use and Application
                    8.1. Regional Dashboard
                    8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
                        8.2.1. U.S.
                            8.2.1.1. Key country dynamics
                            8.2.1.2. Regulatory framework/ reimbursement structure
                            8.2.1.3. Competitive scenario
                            8.2.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 9. Competitive Landscape
                    9.1. Company/Competition Categorization
                    9.2. Vendor Landscape
                        9.2.1. List of key distributors and channel partners
                        9.2.2. Key company market share analysis, 2024
                        9.2.3. Baxter International Inc.
                            9.2.3.1. Company overview
                            9.2.3.2. Financial performance
                            9.2.3.3. Drug benchmarking
                            9.2.3.4. Strategic initiatives
                        9.2.4. AstraZeneca
                            9.2.4.1. Company overview
                            9.2.4.2. Financial performance
                            9.2.4.3. Drug benchmarking
                            9.2.4.4. Strategic initiatives
                        9.2.5. AbbVie Inc.
                            9.2.5.1. Company overview
                            9.2.5.2. Financial performance
                            9.2.5.3. Drug benchmarking
                            9.2.5.4. Strategic initiatives
                        9.2.6. B. Braun Melsungen AG
                            9.2.6.1. Company overview
                            9.2.6.2. Financial performance
                            9.2.6.3. Drug benchmarking
                            9.2.6.4. Strategic initiatives
                        9.2.7. Fresenius SE & Co. KgaA
                            9.2.7.1. Company overview
                            9.2.7.2. Financial performance
                            9.2.7.3. Drug benchmarking
                            9.2.7.4. Strategic initiatives
                        9.2.8. Pfizer
                            9.2.8.1. Company overview
                            9.2.8.2. Financial performance
                            9.2.8.3. Drug benchmarking
                            9.2.8.4. Strategic initiatives
                        9.2.9. Hospira Inc.
                            9.2.9.1. Company overview
                            9.2.9.2. Financial performance
                            9.2.9.3. Drug benchmarking
                            9.2.9.4. Strategic initiatives
                        9.2.10. Aspen Pharmacare Holdings Limited
                            9.2.10.1. Company overview
                            9.2.10.2. Financial performance
                            9.2.10.3. Drug benchmarking
                            9.2.10.4. Strategic initiatives
                        9.2.11. Hikama Pharmaceuticals plc
                            9.2.11.1. Company overview
                            9.2.11.2. Financial performance
                            9.2.11.3. Drug benchmarking
                            9.2.11.4. Strategic initiatives
                        9.2.12. Abbott Laboratories
                            9.2.12.1. Company overview
                            9.2.12.2. Financial performance
                            9.2.12.3. Drug benchmarking
                            9.2.12.4. Strategic initiatives

List of Tables

Table 1 List Of Abbreviation
Table 2 U.S. General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
Table 3 U.S. General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 4 U.S. General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
Table 5 U.S. General Anesthesia Drugs Market, Application, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 U.S. General Anesthesia Drugs Market: Market Outlook
Fig. 10 Colorectal Surgery Competitive Insights
Fig. 11 Parent market outlook
Fig. 12 Related/ancillary market outlook
Fig. 13 U.S. General Anesthesia Drugs Market Driver Impact
Fig. 14 U.S. General Anesthesia Drugs Market Restraint Impact
Fig. 15 U.S. General Anesthesia Drugs Market Strategic Initiatives Analysis
Fig. 16 U.S. General Anesthesia Drugs Market: Drug Movement Analysis
Fig. 17 U.S. General Anesthesia Drugs Market: Drug Outlook And Key Takeaways
Fig. 18 Sevoflurane market estimates and forecast, 2018 - 2030
Fig. 19 Propofol market estimates and forecast, 2018 - 2030
Fig. 20 Dexmedetomidine market estimates and forecast, 2018 - 2030
Fig. 21 Remifentanil market estimates and forecast, 2018 - 2030
Fig. 22 Desflurane market estimates and forecast, 2018 - 2030
Fig. 23 Midazolam market estimates and forecast, 2018 - 2030
Fig. 24 Others market estimates and forecast, 2018 - 2030
Fig. 25 U.S. General Anesthesia Drugs Market: Route of Administration Movement Analysis
Fig. 26 U.S. General Anesthesia Drugs Market: Route of Administration Outlook And Key Takeaways
Fig. 27 Intravenous market estimates and forecast, 2018 - 2030
Fig. 28 Inhaled market estimates and forecast, 2018 - 2030
Fig. 29 U.S. General Anesthesia Drugs Market: End Use Movement Analysis
Fig. 30 U.S. General Anesthesia Drugs Market: End Use Outlook And Key Takeaways
Fig. 31 Hospitals market estimates and forecast, 2018 - 2030
Fig. 32 Ambulatory Surgical Centers market estimates and forecast, 2018 - 2030
Fig. 33 Others market estimates and forecast, 2018 - 2030
Fig. 34 U.S. General Anesthesia Drugs Market: Application Movement Analysis
Fig. 35 U.S. General Anesthesia Drugs Market: Application Outlook And Key Takeaways
Fig. 36 Heart Surgeries market estimates and forecast, 2018 - 2030
Fig. 37 Cancer market estimates and forecast, 2018 - 2030
Fig. 38 General Surgery market estimates and forecast, 2018 - 2030
Fig. 39 Knee and hip replacements market estimates and forecast, 2018 - 2030
Fig. 40 Other market estimates and forecast, 2018 - 2030
Fig. 41 Market share of key market players- U.S. General Anesthesia Drugs Market